
Brewer brothers bank on concept that no bodies are alike
WITH the growing obsession with health and wellness, more of us are paying closer attention to what goes into our bodies and how it makes us feel. The push for better living is ubiquitous but despite noise from superfood fads and trendy supplements, there are those who quietly (and passionately) champion substance over flashiness. One example is kombucha – the tangy, fizzy, fermented tea that has been bubbling its way into mainstream diets for its potent health benefits.
Power of gut
Often hailed as a probiotic powerhouse, kombucha is rich in beneficial bacteria and yeasts. These natural microbes can help regulate digestion, strengthen immunity and improve the balance of gut flora, an area of increasing interest in health science. Research has suggested a strong link between gut health and metabolic function, inflammation and even mood regulation.
In short, a happy gut might just lead to a happier you. Unlike soft drinks or heavily processed 'wellness' products, kombucha is fermented using a culture of bacteria and yeast known as a 'scoby' (Symbiotic Culture Of Bacteria and Yeast), and when brewed properly, delivers a punch in terms of flavour and function.
Visionary brothers
Among Malaysia's growing community of artisanal brewers is Finding Hylas, a kombucha brand born not just out of curiosity, but a deep belief in personalised wellness. Siblings Brian and Justin Yee recently shared with theSun their philosophy and approach to brewing this fermented drink.
'We are only two years apart and we grew up doing everything together such as sports, (having mutual) friends, even sharing a room. It only felt natural that we would one day build something together too,' Bryan said.
Bryan, a chemical engineer by training, and Justin, a physiotherapist, were raised in a family of entrepreneurs. That spirit of independence shaped their mindset early on. But, it was not until the Covid-19 lockdowns thatkombucha entered their lives through an unlikely source.
'Our mum started brewing it as a hobby. We were mildly curious about this alien-looking fermented tea. We started trying small batches and selling them to friends and family,' Justin recalled.
From curiosity to calling
While many might treat this as nothing more than a source of side income, the brothers saw something more.
'What really piqued our interest was researching and experimenting with new techniques and flavours, but the real breakthrough came when we started really listening to our customers,' explained Bryan.
That listening led them to their unique model, which is personalised kombucha tailored to individual health needs and taste preferences. Far from mass-producing a generic product, Finding Hylas offers a subscription-based service with custom blends in every delivery.
'It became a way to care for people. When we interact with our subscribers, it does not feel like labour but it feels meaningful,' Justin said.
Personalised offerings
Hylas operates on the principle of 'many sizes for all', recognising no two bodies or health journeys are exactly alike. Each batch starts with a rotating base flavour, ensuring no two orders taste the same back-to-back. On top of that, ingredients are tailored to support wellness goals. Examples include ginger for bloating, turmeric and blueberry for inflammation, and so on.
'We do not want to tie people down to one plan. Health changes across seasons of life. If kombucha does not work for you, we will tell you to try something else. That is why we do not do commitment periods. For any given batch, we might make up to 72 different customisations and we are always going through research papers and clinical studies to make sure the doses we use are actually effective,' Justin explained.
The brothers' scientific background and clinical eye give Hylas a unique edge. But, some of their most valuable insights come from customer feedback.
'We had one subscriber struggling with psoriasis patches who had tried everything. Through trial and error, we developed a blend that actually helped. Now, we use that formulation to help others with similar issues,' Bryan shared.
Lessons from the journey
The startup path has not always been smooth, but Bryan and Justin have gained perspective.
'Social media glorifies hustle culture such as posting three times a day, work 7am to 10pm – or you are lazy. But, we are limited beings. Work matters, but it would not fully satisfy us.'
Instead, they have learned to delegate, support one another and keep the business sustainable, not just financially, but emotionally too.
The future of Hylas looks anything but static. From wild limited-edition flavours to event-exclusive brews, this year promises more experimentation and expression.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Star
4 hours ago
- The Star
China's first foreign-owned hospital seeks more medical tourists
BEIJING: A Singapore hospital operator wants more international patients to seek treatment at its new medical centre in China, as foreign healthcare providers eye medical tourism as a new growth area in the world's second-largest economy. Perennial Holdings Pte's US$139 million hospital opened earlier this year in the northern city of Tianjin, and is the first fully foreign-owned medical facility in the mainland. The hospital aims to derive 30% of its revenue during its first year of operation from patients visiting from Russia to the Middle East and South-East Asia - hoping China will become an emerging destination for medical tourism that can compete with established regional rivals Singapore, Thailand and Japan. Perennial's focus on luring overseas patients to Tianjin came after China last year moved to allow private hospitals to be fully owned by foreign entities, which had previously needed a Chinese business partner. China's health regulator has since encouraged the Tianjin facility to differentiate itself from the country's public hospitals, hospital president Daniel Liu said in an interview this week. "Medical tourism has yet to become an industry in China, but it's showing promise. We hope to make the pie bigger,' he said. "Some specialities in the Chinese healthcare system have grown in the past two decades, to a point that measures up to international standards.' Private healthcare providers have faced headwinds operating in China as the country's post-Covid economic slump weighed on their main clientele - expats and well-off domestic customers with commercial insurance coverage. Some private hospitals and clinics have closed shop in recent months, while others have had to lower their prices, according to local media. China can be appealing to medical tourists in part due to a speedier diagnosis and treatment process that can get slowed down by rigid referral systems and a lack of resources in other countries. Still, luring global patients to China for treatment - especially when it comes to entering the country - still faces hurdles. China doesn't currently have a visa option for medical tourism, and the visa-free programme it's rolled out to more than 40 countries sometimes only grants stays of under a month - too short for some patients needing to undergo surgery and subsequent recovery. Earlier this year, hospital chiefs and medical experts proposed creating a new visa for medical tourism at China's annual parliamentary session. The move to expand medical tourism also dovetails with Beijing's goal to encourage more inbound travel. Some northeast China hospitals are already frequented by patients from neighbouring Russia, while southern provinces are welcoming patients from South-East Asia as access to Chinese medical care becomes part of the government's tourism push, state agency Xinhua reported. Perennial's Tianjin hospital is even hoping to bring in patients from as far as the UK, where private care is pricey and long waiting lists for the National Health Service have delayed treatments and even diagnoses of certain conditions. To meet future demand from international clients, Perennial is working to recruit medical staff from Singapore and finalise global medical insurance coverage, Liu said. - Bloomberg


The Star
19 hours ago
- The Star
G-Dragon, Le Sserafim, Babymonster push on with overseas concerts amid Covid-19 surge in Asia
Babymonster performs during its world tour "Hello Monsters" in Singapore on May 17. - Photo: YG Entertainment SEOUL: Despite the recent surge in the number of Covid-19 cases across parts of Asia, K-pop stars, including G-Dragon, Le Sserafim and Babymonster, are pressing ahead with their overseas concerts. According to the Korea Disease Control and Prevention Agency (KDCA) on Monday (June 2), countries including China, Thailand and Singapore have recently reported a notable increase in Covid-19 cases. While the situation in Korea remains relatively stable, the agency warned that a summer resurgence is possible due to international travel and regional outbreaks. The NB.1.8.1 variant — now dominant in the affected countries — is known for its strong transmissibility and immune-evasive properties, although its severity and fatality rate remain relatively low. The KDCA is advising high-risk travelers to these countries to get vaccinated before departure. G-Dragon. - Photo: Galaxy Corporation G-Dragon of Big Bang is currently on his 'Ubermensch' world tour, performing across nine Asian cities including Taipei, Kuala Lumpur, Jakarta, Hong Kong and Bangkok as well as Sydney and Melbourne in Australia. He is slated to perform in Macao for three concerts starting June 7. Asked whether shows in Southeast Asia might be canceled due to COVID-19 concerns, his agency Galaxy Corporation told The Korea Herald, 'We don't know at this point.' G-Dragon recently called off his "G-Dragon Media Exhibition: Ubermensch" in Shanghai, which was originally scheduled to run from May 30 to June 22. While the agency cited 'unforeseen circumstances beyond our control' as the reason for the cancellation, the uptick in COVID-19 cases in China is widely suspected as a contributing factor. Babymonster, also on an Asia tour, wrapped up its 'Hello Monsters' concerts in Singapore and Hong Kong in May and is preparing for its final Southeast Asian stop in Bangkok from June 7-8. YG Entertainment confirmed it has no plans to postpone or cancel the shows. 'We're monitoring the situation closely, but the outbreak is limited to certain regions. Everything is proceeding as planned,' a YG official told The Korea Herald on Wednesday. Le Sserafim is scheduled to perform in Taiwan and Hong Kong in July, followed by concerts in the Philippines, Thailand and Singapore in August as part of its 'Easy Crazy Hot' world tour. Source Music's parent company, Hybe, also confirmed that all shows will proceed as scheduled. JYP Entertainment's acts — Niziu, Nmixx and Xdinary Heroes — are also expected to hold small-scale performances in Hong Kong, Macao and Taiwan, respectively, in the second half of the year, with no changes announced. An industry official noted that unless governments issue specific warnings or event restrictions, K-pop agencies are unlikely to take unilateral action regarding concert postponements. 'There aren't any government guidelines like we saw during the height of the pandemic, so it's hard for companies to take preemptive action on their own,' one agency source said. Another industry official echoed the sentiment: 'Without national-level advisories, it's difficult for agencies to make those decisions independently.' - The Korea Herald/ANN


The Star
a day ago
- The Star
Exclusive-CDC expert resigns from COVID vaccines advisory role, sources say
FILE PHOTO: Vials labelled "VACCINE Coronavirus COVID-19" and a syringe are seen in front of a displayed U.S. flag in this illustration taken December 11, 2021. REUTERS/Dado Ruvic/Illustration/File Photo (Reuters) -Pediatric infectious disease expert Dr. Lakshmi Panagiotakopoulos of the U.S. CDC resigned on Tuesday as co-leader of a working group that advises outside experts on COVID-19 vaccines and is leaving the agency, two sources familiar with the move told Reuters. Panagiotakopoulos said in an email to work group colleagues that her decision to step down was based on the belief she is "no longer able to help the most vulnerable members" of the U.S. population. In her role at the Centers for Disease Control and Prevention's working group of the Advisory Committee on Immunization Practices, she co-led the gathering of information on topics for presentation. Her resignation comes one week after Health Secretary Robert F. Kennedy Jr., a long-time vaccine skeptic who oversees the CDC, the Food and Drug Administration and the National Institutes of Health, said the COVID vaccine for healthy children and healthy pregnant women had been removed from the CDC's recommended immunization schedule. The move was a departure from the process in which ACIP experts meet and vote on changes to the immunization schedule or recommendations on who should get vaccines before the agency's director made a final call. The committee had not voted on the changes announced by Kennedy and the CDC does not yet have a permanent director. Two days after Kennedy's announcement, the CDC published a vaccine schedule online saying that COVID-19 vaccines remain an option for healthy children aged 6 months to 17 years when parents and doctors agree that it is needed. It had previously recommended updated COVID vaccines foreveryone aged six months and older, following the guidance ofthe panel of outside experts. Two sources said Panagiotakopoulos did not include a specific reason for her departure. Panagiotakopoulos did not return requests for comment. "Unfortunately for me, this is a personal decision," Panagiotakopoulos wrote in an email to members of the working group that was read to Reuters by a source who received it. "My career in public health and vaccinology started with a deep-seated desire to help the most vulnerable members of our population, and that is not something I am able to continue doing in this role." The committee is scheduled to meet on June 25-27 and is expected to deliberate and vote on recommendations for use of COVID-19 vaccines, according to one of the sources who was not authorized to speak publicly. (Reporting by Julie Steenhuysen in Chicago, Michael Erman in New York and Dan Levine in San Francisco; Editing by Caroline Humer and Bill Berkrot)